Even though DCLK1 has emerged as a cancer stem cell marker candidate for pancreatic cancer, intestinal cancer, and colorectal cancer, the structural knowledge of the putative inhibitors with various types of scaffolds targeting the DCLK1 kinase domain remains currently limited. This evidence concerns the gene DCLK1 and colorectal cancer.